ISPOR - EE415 Cost Utility Analysis of Ocrelizumab Versus Fingolimod in Relapsing Remitting Multiple Sclerosis Patients in Egypt from Payor Perspective

Full Text

EE415 Cost Utility Analysis of Ocrelizumab Versus Fingolimod in Relapsing Remitting Multiple Sclerosis Patients in Egypt from Payor Perspective

Abstract

Authors

A Ibrahim I Anan

Back to Volume 25, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now